Structure-based Repurposing of FDA-approved Drugs As TNF-α Inhibitors
Overview
Authors
Affiliations
Kim S, Ahn G, Kim H, Je J, Kim K, Jeon Y Mar Drugs. 2020; 18(11).
PMID: 33114618 PMC: 7692396. DOI: 10.3390/md18110529.
Aurone derivatives as Vps34 inhibitors that modulate autophagy.
Li G, Boyle J, Ko C, Zeng W, Wong V, Wan J Acta Pharm Sin B. 2019; 9(3):537-544.
PMID: 31193773 PMC: 6543056. DOI: 10.1016/j.apsb.2019.01.016.
Melagraki G, Ntougkos E, Papadopoulou D, Rinotas V, Leonis G, Douni E Front Pharmacol. 2018; 9:800.
PMID: 30090063 PMC: 6068282. DOI: 10.3389/fphar.2018.00800.
Design, Synthesis, and Evaluation of Dihydrobenzo[]indole-6-sulfonamide as TNF-α Inhibitors.
Deng X, Zhang X, Tang B, Liu H, Shen Q, Liu Y Front Chem. 2018; 6:98.
PMID: 29670876 PMC: 5893771. DOI: 10.3389/fchem.2018.00098.
Thiopurine Drugs Repositioned as Tyrosinase Inhibitors.
Choi J, Lee Y, Jee J Int J Mol Sci. 2017; 19(1).
PMID: 29283382 PMC: 5796027. DOI: 10.3390/ijms19010077.